XML 30 R17.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stockholders' Equity | 9 Months Ended
--- | ---
Jan. 28, 2022
Share-based Payment Arrangement [Abstract] |
Stockholders' Equity | 9. Stockholders’ Equity Equity Incentive Awards As of January 28, 2022, we have certain equity incentive awards outstanding, which include stock options and restricted stock units (RSUs), including time-based RSUs and performance-based RSUs (PBRSUs). Also outstanding are purchase rights under our Employee Stock Purchase Plan (ESPP). Stock Options Less than 1 million options were outstanding as of January 28, 2022 and April 30, 2021. Information related to our stock options is summarized below (in millions):
|  | Nine Months Ended |
|  | January 28, 2022 |  |  | January 29, 2021 |
Intrinsic value of exercises |  | $ | 13 |  |  | $ | 4 |
Proceeds received from exercises |  | $ | 1 |  |  | $ | 2 |
Fair value of options vested |  | $ | 4 |  |  | $ | 4 |
Restricted Stock Units In the nine months ended January 28, 2022, we granted PBRSUs to certain of our executives. Each PBRSUs has performance-based vesting criteria, in addition to the service-based vesting criteria, such that the PBRSUs cliff-vest at the end of an approximate one, two or three year performance period, which began on the date specified in the grant agreements and typically ends on the last day of the first, second or third fiscal year, respectively, following the grant date. The number of shares of common stock that will be issued to settle most of these PBRSUs at the end of the performance and service period will range from 0% to 200% of a target number of shares originally granted. For most of the PBRSUs granted in the nine months ended January 28, 2022, the number of shares issued will depend upon our Total Stockholder Return (TSR) as compared to the TSR of a specified group of benchmark peer companies (each expressed as a growth rate percentage) calculated as of the end of the performance period. The fair values of these TSR performance-based awards were fixed at grant date using a Monte Carlo simulation model. The aggregate grant date fair value of all PBRSUs granted in the current year was $43 million, which is being recognized to compensation expense over the remaining performance / service periods. The following table summarizes information related to our RSUs, including PBRSUs, (in millions, except fair value):
|  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value |
Outstanding as of April 30, 2021 |  |  | 9 |  |  | $ | 47.75 |
Granted |  |  | 5 |  |  | $ | 79.41 |
Vested |  |  | (3 | ) |  | $ | 48.50 |
Forfeited |  |  | (1 | ) |  | $ | 57.03 |
Outstanding as of January 28, 2022 |  |  | 10 |  |  | $ | 62.30 |
We primarily use the net share settlement approach upon vesting, where a portion of the shares are withheld as settlement of employee withholding taxes, which decreases the shares issued to the employee by a corresponding value. The number and value of the shares netted for employee taxes are summarized in the table below (in millions):
|  | Nine Months Ended |
|  | January 28, 2022 |  |  | January 29, 2021 |
Shares withheld for taxes |  |  | 1 |  |  |  | 1 |
Fair value of shares withheld |  | $ | 69 |  |  | $ | 38 |
Employee Stock Purchase Plan The following table summarizes activity related to the purchase rights issued under the ESPP (in millions):
|  | Nine Months Ended |
|  | January 28, 2022 |  |  | January 29, 2021 |
Shares issued under the ESPP |  |  | 3 |  |  |  | 2 |
Proceeds from issuance of shares |  | $ | 104 |  |  | $ | 90 |
Stock-Based Compensation Expense Stock-based compensation expense is included in the condensed consolidated statements of income as follows (in millions):
|  | Three Months Ended |  |  | Nine Months Ended |
|  | January 28, 2022 |  |  | January 29, 2021 |  |  | January 28, 2022 |  |  | January 29, 2021 |
Cost of product revenues |  | $ | 1 |  |  | $ | 1 |  |  | $ | 3 |  |  | $ | 3 |
Cost of services revenues |  |  | 4 |  |  |  | 2 |  |  |  | 10 |  |  |  | 7 |
Sales and marketing |  |  | 30 |  |  |  | 21 |  |  |  | 85 |  |  |  | 70 |
Research and development |  |  | 19 |  |  |  | 15 |  |  |  | 53 |  |  |  | 49 |
General and administrative |  |  | 10 |  |  |  | 7 |  |  |  | 28 |  |  |  | 20 |
Total stock-based compensation expense |  | $ | 64 |  |  | $ | 46 |  |  | $ | 179 |  |  | $ | 149 |
Income tax benefit for stock-based compensation expense |  | $ | 6 |  |  | $ | 4 |  |  | $ | 15 |  |  | $ | 12 |
As of January 28, 2022, total unrecognized compensation expense related to our equity awards was $499 million, which is expected to be recognized on a straight-line basis over a weighted-average remaining service period of 2.3 years. Stock Repurchase Program As of January 28, 2022, our Board of Directors has authorized the repurchase of up to $14.1 billion of our common stock. Under this program, we may purchase shares of our outstanding common stock through solicited or unsolicited transactions in the open market, in privately negotiated transactions, through accelerated share repurchase programs, pursuant to a Rule 10b5-1 plan or in such other manner as deemed appropriate by our management. The stock repurchase program may be suspended or discontinued at any time. The following table summarized activity related to the stock repurchase program for the nine months ended January 28, 2022 (in millions, except for per share amounts):
Number of shares repurchased |  |  | 4 |
Average price per share |  | $ | 86.63 |
Stock repurchases allocated to additional paid-in capital |  | $ | 10 |
Stock repurchases allocated to retained earnings |  | $ | 340 |
Remaining authorization at end of period |  | $ | 502 |
Since the May 13, 2003 inception of our stock repurchase program through January 28, 2022, we repurchased a total of 344 million shares of our common stock at an average price of $39.58 per share, for an aggregate purchase price of $13.6 billion. Dividends The following is a summary of our activities related to dividends on our common stock (in millions, except per share amounts):
|  | Nine Months Ended |
|  | January 28, 2022 |  |  | January 29, 2021 |
Dividends per share declared |  | $ | 1.50 |  |  | $ | 1.44 |
Dividend payments allocated to additional paid-in capital |  | $ | — |  |  | $ | 30 |
Dividend payments allocated to retained earnings |  | $ | 335 |  |  | $ | 291 |
On February 18, 2022, we declared a cash dividend of $0.50 per share of common stock, payable on April 27, 2022 to holders of record as of the close of business on April 8, 2022. The timing and amount of future dividends will depend on market conditions, corporate business and financial considerations and regulatory requirements. All dividends declared have been determined by us to be legally authorized under the laws of the state in which we are incorporated. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) (AOCI) by component, net of tax, are summarized below (in millions):
|  | Foreign Currency Translation Adjustments |  |  | Defined Benefit Obligation Adjustments |  |  | Unrealized Gains (Losses) on Available- for-Sale Securities |  |  | Unrealized Gains (Losses) on Derivative Instruments |  |  | Total |
Balance as of April 30, 2021 |  | $ | (27 | ) |  | $ | (4 | ) |  | $ | 1 |  |  | $ | — |  |  | $ | (30 | )
Other comprehensive income (loss), net of tax |  |  | (11 | ) |  |  | — |  |  |  | (1 | ) |  |  | 6 |  |  |  | (6 | )
Amounts reclassified from AOCI, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5 | ) |  |  | (5 | )
Total other comprehensive income (loss) |  |  | (11 | ) |  |  | — |  |  |  | (1 | ) |  |  | 1 |  |  |  | (11 | )
Balance as of January 28, 2022 |  | $ | (38 | ) |  | $ | (4 | ) |  | $ | — |  |  | $ | 1 |  |  | $ | (41 | )
The amounts reclassified out of AOCI are as follows (in millions):
|  | Three Months Ended |  |  | Nine Months Ended |  |  |
|  | January 28, 2022 |  |  | January 29, 2021 |  |  | January 28, 2022 |  |  | January 29, 2021 |  |  | Statements of Income Classification
Realized (gains) losses on cash flow hedges |  | $ | (4 | ) |  | $ | 3 |  |  | $ | (5 | ) |  | $ | 11 |  |  | Net revenues

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration